Nitazoxanide: A new broad spectrum antiparasitic agent

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 1, 2004, Pages 43-49

  White Jr , Arthur Clinton ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiparasitic; Cryptosporidiosis; Cryptosporidium; Echinococcus; Fasciola; Giardia; Helminth

Indexed keywords

ALBENDAZOLE; ANTIPARASITIC AGENT; BENZIMIDAZOLE DERIVATIVE; COLUFASE; DAXON; GAMMA INTERFERON ANTIBODY; MEBENDAZOLE; METRONIDAZOLE; NICLOSAMIDE; NITAZOXANIDE; PLACEBO; PRAZIQUANTEL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FASCIOLIASIS; GASTROINTESTINAL TOXICITY; GIARDIASIS; HELMINTHIASIS; HUMAN; IN VITRO STUDY; NAUSEA AND VOMITING; NONHUMAN; TAPEWORM INFECTION;

EID: 2942590820     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.1.43     Document Type: Article

References (41)

1. White AC Jr. The disappearing arsenal of antiparasitic drugs. N. Engl. J. Med. 343, 1273 1274 (2000).
2. White AC Jr. Nitazoxanide: an important advance in antiparasitic therapy. Am. J. Trop. Med. Hyg. 68, 382 383 (2003).
3. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am. J. Trop. Med. Hyg. 33, 511-512 (1984).
4. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 18, 95 97 (2002).
5. Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. J. Clin. Pharmacol. Ther. 40, 213 220 (2002).
6. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38, 387 394 (2000).
7. Stockis A, De Bruyn S, Gengler C, Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol. Ther. 40, 221-227 (2002).
8. Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92, 663-666 (1998).
9. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 42, 1959-1965 (1998).
10. Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J. Antimicrob. Chemother. 45, 453-456 (2000).
11. Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother. 46, 57-60 (2000).
12. Blagburn BL, Drain KL, Land TM et al. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother. 42, 2877-2882 (1998).
13. Li X, Brasseur P, Agnamey P et al. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol. (Praha) 50, 19-22 (2003).
14. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56, 637-939 (1997).
15. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184, 103-106 (2001).
16. Amadi B, Mwiya M, Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375-1380 (2002).
17. Brantley RK, Williams KR, Silva TM et al. AIDS-associated diarrhea and wasting in northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Brazil J. Infect. Dis. 7, 16-22 (2003).
18. + count so important? Clin. Infect. Dis. 33, 1609-1611 (2001).
19. Okhuysen PC, Robinson P, Nguyen MT et al. Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution. AIDS 15, 802-804 (2001).
20. Vasquez TO, Alvarez Ch R, Gonzales SN et al. [Diagnosis and treatment of cyclospora cayetanensisinfection in paediatric patients]. Rev. Gastroenterol. Peru 18, 116-120 (1998).
21. Diaz E, Mondragon J, Ramirez E , Bernal R. Short report: epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am. J. Trop. Med. Hyg. 68, 384-385 (2003).
22. Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91, 701-703 (1997).
23. Bialek R, Overkamp D, Rettig I, Knobloch J. Case report: nitazoxanide treatment failure in chronic isosporiasis. Am. J. Trop. Med. Hyg. 65, 94-95 (2001).
24. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 49, 103-111 (2002).
25. Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J. Eukaryot. Microbiol. 49, 201-208 (2002).
26. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184, 381-384 (2001).
27. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment. Pharmacol. Ther. 15, 1409-1415 (2001).
28. Abboud P, Lemee V, Gargala G et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. 32, 1792-1794 (2001).
29. Bicart-See A, Massip P, Linas MD, Datry A. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob. Agents Chemother. 44, 167-168 (2000).
30. Abaza H, El-Zayadi AH, Kabil SM, Rizk H. Nitazoxanide in the treatment of patients with intestinal protozoan and helminth infections: a report on 546 patients in Egypt. Curr. Ther. Res. 58, 116-121 (1998).
31. Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am. J. Trop. Med. Hyg. 66, 251-254 (2002).
32. Ortiz JJ, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans. R. Soc. Trop. Med. Hyg. 96, 193-196 (2002).
33. Stettler M, Fink R, Walker M et al. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob. Agents Chemother. 47, 467-474 (2003).
34. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Trop. Med. Hyg. 92, 103-104 (1998).
35. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment. Pharmacol. Ther. 17, 265-270 (2003).
36. Millan JC, Mull R, Freise S, Richter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am. J. Trop. Med. Hyg. 63, 264-269 (2000).
37. Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin. Infect. Dis. 33, 1-5 (2001).
38. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40, 2266-2270 (1996).
39. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44, 2254-2258 (2000).
40. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother. 42, 2836-2840 (1998).
41. Yamamoto Y, Hakki A, Friedman H et al. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with antivacuolating toxin activity. Chemotherapy 45, 303-312 (1999).